Prelude Capital Management’s Abeona Therapeutics ABEO Stock Holding History
Bought
Maintained
Sold
Other funds holding ABEO
ACM
AIC
Prelude Capital Management's ABEO Position: Q3 2026 in Review
Prelude Capital Management reduced its Abeona Therapeutics (ABEO) stake by 49% in Q3 2026, selling an estimated $172K and leaving 28,304 shares worth $149K. The position accounts for 0.01% of the portfolio, ranked #1165.
Prelude Capital Management first reported a position in ABEO in Q2 2015 and has held it in 24 quarters since. The position peaked at $586K in Q4 2025. 114 funds tracked by Wall St. Rank hold ABEO as of Q3 2026.
- Prelude Capital Management held 28,304 shares of Abeona Therapeutics worth $149K as of Q3 2026.
- Prelude Capital Management sold 27,634 Abeona Therapeutics shares in Q3 2026, an estimated $172K.
- Abeona Therapeutics made up 0.01% of Prelude Capital Management's portfolio in Q3 2026, its #1165 holding.
- Prelude Capital Management first reported a position in Abeona Therapeutics in Q2 2015 and has held it in 24 quarters since.
- Prelude Capital Management's Abeona Therapeutics position peaked at $586K in Q4 2025.
- 114 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2026.
Based on Prelude Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.